Asthma treatment guidelines
I'll look up the medical library skill first, then search for asthma treatment guidelines.
Reading File
Now I'll run parallel searches across the medical library and PubMed simultaneously.
Finding Sources
Searching PubMed
"asthma"[MeSH Terms] AND "guideline"[pt]
Searching the Web
asthma treatment guidelines 2025 GINA stepwise therapy
Now let me search the library more broadly for asthma content and get the biologic guideline abstract.
Finding Sources
Reading Article
PMID: 41005695
Excellent findings. Now let me read the most relevant textbook sections for detailed content.
Reading File
Reading File
Reading File
I now have comprehensive, authoritative content from multiple sources. Let me compile the full answer.
Asthma Treatment Guidelines (GINA 2025 / NAEPP)
Overview
Both the Global Initiative for Asthma (GINA) and the National Asthma Education and Prevention Program (NAEPP) use a stepwise approach to asthma management, titrating therapy up or down based on symptom control and exacerbation risk. The cornerstone is inhaled corticosteroid (ICS)-containing therapy for all patients - SABA-only therapy is no longer recommended at any step.
Goals of Treatment
- Achieve symptom control with the least medication and fewest side effects
- Minimize risk of exacerbations, fixed airflow limitation, and medication adverse effects
- Enable normal activity and lung function
- Assessment includes: impairment (symptom frequency, lung function) and risk (exacerbation frequency/severity)
Before stepping up therapy, always address:
- Adherence to medications
- Inhaler technique (identified as the cause of poor control in up to 50% of referred patients)
- Comorbidities (rhinitis, GERD, obesity, OSA)
- Allergen/trigger exposure
GINA 2025 Stepwise Approach (Adults & Adolescents ≥12 years)
GINA now offers two preferred treatment tracks:
Track 1 (Preferred) - Anti-Inflammatory Reliever (AIR) Approach
| Step | Preferred Controller | Reliever |
|---|---|---|
| Step 1 | As-needed low-dose ICS-formoterol | As-needed ICS-formoterol |
| Step 2 | As-needed low-dose ICS-formoterol | As-needed ICS-formoterol |
| Step 3 | Low-dose ICS-LABA maintenance | As-needed low-dose ICS-formoterol |
| Step 4 | Medium-dose ICS-LABA maintenance | As-needed low-dose ICS-formoterol |
| Step 5 | High-dose ICS-LABA ± add-on therapy | As-needed low-dose ICS-formoterol |
At Steps 3-5, the MART regimen (Maintenance and Reliever Therapy) uses ICS-formoterol as both maintenance and as-needed relief.
Track 2 - Traditional Fixed-Dose Approach
| Step | Preferred Controller | Reliever |
|---|---|---|
| Step 1 | Low-dose ICS taken whenever SABA used | As-needed SABA |
| Step 2 | Daily low-dose ICS | As-needed SABA |
| Step 3 | Low-dose ICS-LABA | As-needed SABA |
| Step 4 | Medium-dose ICS-LABA | As-needed SABA |
| Step 5 | High-dose ICS-LABA ± add-on therapy | As-needed SABA |
Source: Murray & Nadel's Textbook of Respiratory Medicine, Table 62.3
Step-Up / Step-Down Principles
- Step up when asthma is uncontrolled at current therapy (after confirming adherence/technique)
- Step down after 3 months of well-controlled asthma - use lowest effective dose
- Reassess control every 2-3 months
- Follow-up within 1-4 weeks after any treatment change
Pediatric-Specific Guidance (NAEPP 2020 Focused Updates)
| Age group | Key guidance |
|---|---|
| 0-4 years (intermittent/URI-triggered) | Short course ICS + SABA at onset of viral infection |
| 5-11 years (Steps 3-4) | SMART therapy: single ICS-formoterol inhaler used both daily and as-needed |
| ≥12 years (Steps 3-4) | SMART therapy preferred; LAMA add-on at Step 3+ |
| ≥5 years (Steps 2-4) | Subcutaneous allergen immunotherapy if sensitized |
Source: Harriet Lane Handbook, 23rd ed., Chapter 25
Add-On Therapies for Severe Asthma (Step 5)
Before starting biologics, confirm:
- High-dose ICS-LABA is being taken with good adherence/technique
- Comorbidities are treated (rhinitis, GERD, obesity)
- Asthma phenotyping/endotyping has been done
Biologic Agents
| Drug | Target | Indication |
|---|---|---|
| Omalizumab | Anti-IgE | Allergic asthma, ≥5 years |
| Mepolizumab / Reslizumab | Anti-IL-5 | Eosinophilic asthma |
| Benralizumab | Anti-IL-5Rα | Eosinophilic asthma |
| Dupilumab | Anti-IL-4Rα (IL-4/IL-13) | Type 2 asthma, ≥12 years |
| Tezepelumab | Anti-TSLP | Severe uncontrolled asthma (broad phenotype) |
A 2026 ACCP systematic review (PMID: 41005695) notes that biologic selection depends on quality of life impairment, baseline FEV1, exacerbation frequency, baseline OCS use, endotype, and biomarkers (blood eosinophils, IgE, FeNO). Head-to-head comparisons remain limited.
Other Step 5 Options
- LAMA (tiotropium): Add-on for uncontrolled asthma on medium-high ICS-LABA; improves lung function and reduces exacerbations
- Low-dose azithromycin (250-500 mg three times/week x 26-48 weeks): For persistent symptomatic asthma at Step 5, particularly non-eosinophilic or neutrophilic phenotype
- Low-dose oral corticosteroids: Last resort; weigh significant side-effect burden
- Leukotriene receptor antagonists (LTRA): Add-on option at multiple steps, especially with comorbid allergic rhinitis
Source: Harrison's Principles of Internal Medicine, 22nd ed., Table 298-5
Biomarkers in Asthma Management
| Biomarker | Use |
|---|---|
| Blood eosinophils | Predict response to anti-IL-5 biologics; ≥300/µL suggests Type 2 |
| Total IgE | Guides omalizumab dosing |
| FeNO | Adjunct diagnostic aid ≥5 years; high values (>50 ppb) predict steroid response |
| Periostin | Emerging marker for IL-13-driven inflammation |
Key 2025 Updates vs. Older Guidelines
- No SABA monotherapy - ICS must accompany all reliever use
- AIR (Anti-Inflammatory Reliever) concept - as-needed ICS-formoterol is safe and effective even at Step 1
- Severe asthma biologics - Type 2 biologics are now standard of care before escalating to oral steroids
- ICS-SABA combination inhaler - GINA now recognizes ICS/albuterol combination as an alternative anti-inflammatory reliever in the US
- Bronchial thermoplasty - No longer routinely recommended (manufacturer discontinued devices)
Acute Exacerbation Management (Brief)
- Mild-moderate: Repeat doses of SABA (or ICS-formoterol on Track 1), oral corticosteroids if not improving
- Severe/status asthmaticus: IV/IM corticosteroids, continuous nebulized SABA, ipratropium, supplemental O2 (target SpO2 93-95%), consider IV magnesium sulfate, escalate to ICU if needed
- Intensification of controller therapy for 3-10 days after exacerbation
Key sources: Harrison's Principles of Internal Medicine 22E (2025) | Murray & Nadel's Textbook of Respiratory Medicine | Harriet Lane Handbook 23rd ed. | ACCP Biologic Guidelines 2026 (PMID: 41005695)
This is a shared conversation. Sign in to Orris to start your own chat.